88497-27-2

Basic information

• Product Name: 6-BROMO-3-PYRIDAZINAMINE
• Synonyms: 6-BROMO-3-PYRIDAZINAMINE;2-Amino-5-bromopyridazine;6-Bromo-3-pyridazineamine;6-Bromo-3-pyridazinamine ,97%;3-Amino-6-bromopyridazine;3-Bromo-6-aminopyridazine;3-PyridazinaMine,6-broMo- ;6-BROMO-3-PYRIDAZIMINE
• CAS NO: 88497-27-2
• Molecular Formula: C₄H₄BrN₃
• Molecular Weight: 174
• Product Categories: Amines;Pyrazines, Pyrimidines & Pyridazines;Pyrazines, Pyrimidines & Pyridazines
• Mol File: 88497-27-2.mol
• Article Data: 3

Chemical Properties

• Melting Point: 194 °C
• Boiling Point: 353.2°C at 760 mmHg
• Flash Point: 167.4°C
• Appearance: /
• Density: 1.844g/cm³
• Vapor Pressure: 3.63E-05mmHg at 25°C
• Refractive Index: 1.648
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 4.06±0.10(Predicted)
• CAS DataBase Reference: 6-BROMO-3-PYRIDAZINAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-3-PYRIDAZINAMINE(88497-27-2)
• EPA Substance Registry System: 6-BROMO-3-PYRIDAZINAMINE(88497-27-2)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38-22
• Safety Statements: 22-26-36/37/39
• RIDADR: 2811
• Hazardous Substances Data: 88497-27-2(Hazardous Substances Data)

Usage

Uses

6-bromopyridazin-3-amine (cas# 88497-27-2) is a useful research chemical.

Chemical Properties

Light brown to yellow solid

InChI:InChI=1/C4H4BrN3/c5-3-1-2-4(6)8-7-3/h1-2H,(H2,6,8)

Upstream product

• 17973-86-3 3,6-dibromopyridazine 

Downstream Products

• 5469-70-5 3-aminopyridazine 
• 1159977-65-7 6-bromoimidazo[1,2-b]pyridazine 
• 66346-94-9 [6-(4-methylpiperazin-1-yl)pyridazin-3-yl]amine 
• 1402146-84-2 C₁₆H₁₃N₃ 
• 1206487-35-5 4,6-dibromopyridazin-3-amine 
• 1126365-54-5 N-[5-(6-aminopyridazin-3-yl)-2-methylphenyl]-4-(pyridin-2-ylmethoxy)benzamide 
• 1296644-77-3 C₂₃H₂₀Cl₂N₆ 

Relevant articles and documents

COMBINATIONS FOR THE TREATMENT OF CANCER

The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.

COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER

The present invention relates to a combination comprising an Mps-1 kinase inhibitor and a mitotic inhibitor. The present invention also relates to the use of said combination for the treatment of cancer, in particular of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.